Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
Pleuroplumonary fibrosis is an uncommon but potentially serious adverse effect of bromocriptine used in the treatment of Parkinson's disease. Two cases of this reaction, which occurred 12 months and 5 months respectively after commencing therapy are here reported. In both instances prompt clinical and radiological improvement occurred when bromocriptine intake was ceased. Fibrotic reactions to bromocriptine may be mediated by a serotonergic mechanism. Periodic monitoring of pulmonary symptoms is warranted in patients receiving bromocriptine treatment for Parkinson's disease.
Todman
D H
DH
Department of Neurology, Repatriation General Hospital, Brisbane.
Oliver
W A
WA
Edwards
R L
RL
D000368:Aged; D001545:Benserazide / Q000627:therapeutic use; D001971:Bromocriptine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D012701:Serotonin / Q000378:metabolism
D012701:Serotonin; D001971:Bromocriptine; D007980:Levodopa; D001545:Benserazide